67 related articles for article (PubMed ID: 4742501)
1. Response of advanced breast cancer to two dosage regiments of 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU; NSC-409962).
Bonnet JD; Brownlee RW; Vaitkevicius VK; Talley RW
Cancer Chemother Rep; 1973 Apr; 57(2):231-4. PubMed ID: 4742501
[No Abstract] [Full Text] [Related]
2. Clinical evaluation of 1,3-bis(2-chloroethyl)-nitrosourea (BCNU; NSC-409962) with fluoxymesterone (NSC-12165) in the treatment of solid tumors.
Reyes ES; Talley RW; O'Bryan RM; Gastesi RA
Cancer Chemother Rep; 1973 Apr; 57(2):225-30. PubMed ID: 4582564
[No Abstract] [Full Text] [Related]
3. Evaluation of 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU; NSC-409962) in the management of patients with advanced breast cancer.
Ahmann DL; Hahn RG; Bisel HF
Cancer Chemother Rep; 1972 Feb; 56(1):93-4. PubMed ID: 5030810
[No Abstract] [Full Text] [Related]
4. Adriamycin, 1,3-bis (2-chloroethyl)-1-nitrosourea (BCNU, NSC 409962) and cyclophosphamide therapy of drug-resistant metastatic breast carcinoma.
Presant CA; Van Amburg A; Klahr C
Cancer; 1977 Sep; 40(3):987-93. PubMed ID: 902247
[TBL] [Abstract][Full Text] [Related]
5. 5-Fluorouracil (5-Fu; NSC-19893), 5-(3,3-dimethyl-1-triazeno)imidazole-4-carboxamide (NSC-45388), vincristine (NSC-67574), and 1,3-bis(2-chloroethyl)-2-nitrosourea (BCNU; NSC-409962) given concomitantly in the treatment of solid tumors in man.
van Eden EB; Falkson G; van Dyk JJ; van der Merwe AM; Falkson HC
Cancer Chemother Rep; 1972 Feb; 56(1):107-47. PubMed ID: 5030803
[No Abstract] [Full Text] [Related]
6. Treatment of Hodgkin's disease and other cancers with 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU; NSC-409962).
Marsh JC; DeConti RC; Hubbard SP
Cancer Chemother Rep; 1971 Dec; 55(5):599-606. PubMed ID: 4334161
[No Abstract] [Full Text] [Related]
7. Evaluation of cyclophosphamide (NSC-26271) and 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU; NSC-409962) in the treatment of patients with inoperable or disseminated lung cancer.
Ahmann DL; Carr DT; Coles DT; Hahn RG
Cancer Chemother Rep; 1972 Jun; 56(3):401-3. PubMed ID: 19051501
[TBL] [Abstract][Full Text] [Related]
8. BCNU (NSC-409962) in the treatment of advanced Hodgkin's disease, lymphosarcoma, and reticulum cell sarcoma.
Rege VB; Owens AH
Cancer Chemother Rep; 1974; 58(3):383-92. PubMed ID: 4601668
[No Abstract] [Full Text] [Related]
9. Adriamycin, 1,3-bis (2-chloroethyl)-1-nitrosourea (BCNU-NSC 409462), and cyclophosphamide in refractory adenocarcinoma of the breast and other tumors.
Presant CA; Kolhouse JF; Klahr C
Cancer; 1976 Feb; 37(2):620-8. PubMed ID: 1253101
[TBL] [Abstract][Full Text] [Related]
10. 1.3 Bis-(2 chloroethyl)-1-nitrosourea and streptozotocin chemotherapy.
Lokich JJ; Chawla PL; Frei E
Clin Pharmacol Ther; 1975 Mar; 17(3):374-8. PubMed ID: 123490
[TBL] [Abstract][Full Text] [Related]
11. Amphotericin B plus 1,3-bis (2-chloroethyl)-1-nitrosourea (BCNU-NSC no. 409962) in advanced cancer. Phase I and preliminary phase II results.
Presant CA; Klahr C; Olander J; Gatewood D
Cancer; 1976 Nov; 38(5):1917-21. PubMed ID: 991105
[TBL] [Abstract][Full Text] [Related]
12. Combined therapy with cytosine arabinoside (NSC-63878) and 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU; NSC-409962) for advanced solid tumors.
Kinne DW; Humphrey EW
Cancer Chemother Rep; 1972 Feb; 56(1):53-9. PubMed ID: 5030809
[No Abstract] [Full Text] [Related]
13. 1,3-Bis(2-chloroethyl)-1-nitrosourea (BCNU; NSC-409962) given alone and combined with antimetabolites in the treatment of advanced solid tumors.
Cohen SM; Weiner MJ; Greenspan EM
Cancer Chemother Rep; 1972 Dec; 56(6):751-4. PubMed ID: 4660631
[No Abstract] [Full Text] [Related]
14. Proceedings: Superiority of adriamycin over oral nitrosoureas in patients with advanced breast carcinoma. A Southwest Cancer Chemotherapy study Group study.
Gottlieb JA; Rivkin SE; Spigel SC; Hoogstraten B; O'Bryan RM; Delaney FC; Singhakowinta A
Cancer; 1974 Feb; 33(2):519-26. PubMed ID: 4812769
[No Abstract] [Full Text] [Related]
15. Toxicity study of BCNU (NSC-409962) given orally.
Lessner HE; Vogler WR
Cancer Chemother Rep; 1974; 58(3):407-11. PubMed ID: 4601671
[No Abstract] [Full Text] [Related]
16. Phase II study of 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU; NSC-409962) in the treatment of bronchogenic carcinoma.
Olshin S; Siddiqui S; Firat D
Cancer Chemother Rep; 1972 Apr; 56(2):259-61. PubMed ID: 5043228
[No Abstract] [Full Text] [Related]
17. [Alternative treatment with carmustine, vindesine and tamoxifen in previously cytostaticly (VAC, FMC) treated patients with metastatic breast cancer].
Massner B; Voss I; Queisser W; Drings P; Fritze D; Westerhausen M
Onkologie; 1982 Aug; 5 Suppl():46-51. PubMed ID: 6752791
[TBL] [Abstract][Full Text] [Related]
18. Pulmonary fibrosis after prolonged therapy with 1,3-bis (2-chloroethyl)-1-nitrosourea.
Crittenden D; Tranum BL; Haut A
Chest; 1977 Sep; 72(3):372-3. PubMed ID: 891293
[TBL] [Abstract][Full Text] [Related]
19. 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU; NSC-409962) given concomitantly with cytosine arabinoside (NSC-63878) in the treatment of cancer.
van Eden EB; Falkson HC; Falkson G
Cancer Chemother Rep; 1970 Oct; 54(5):347-59. PubMed ID: 5514624
[No Abstract] [Full Text] [Related]
20. Amphotericin B induction of sensitivity to adriamycin, 1,3-bis (2-chloroethyl)-1-nitrosourea (BCNU) plus cyclophosphamide in human neoplasia.
Presant CA; Klahr C; Santala R
Ann Intern Med; 1977 Jan; 86(1):47-51. PubMed ID: 264783
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
